How I treat Hyperleukocytosis in Acute Myeloid Leukemia€¦ · Röllig & Ehninger How I treat hyperleukocytosis in AML Incidence and pathophysiology In untreated AML, about 5 to
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1 Röllig & Ehninger How I treat hyperleukocytosis in AML
How I treat Hyperleukocytosis in Acute Myeloid Leukemia
Christoph Röllig and Gerhard Ehninger
Medizinische Klinik und Poliklinik I, Universitätsklinikum der Technischen Universität
22 Röllig & Ehninger How I treat hyperleukocytosis in AML
References
1. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J.Clin Oncol. 1987;5(9):1364-1372.
2. Vaughan WP, Kimball AW, Karp JE, et al. Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts. Cancer Treat.Rep. 1981;65(11-12):1007-1013.
3. Cuttner J, Holland JF, Norton L, et al. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. Med.Pediatr.Oncol. 1983;11(2):76-78.
4. Ventura GJ, Hester JP, Smith TL, et al. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am.J.Hematol. 1988;27(1):34-37.
5. Hug V, Keating M, McCredie K, et al. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer. 1983;52(5):773-779.
6. Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br.J.Haematol. 1997;98(2):433-436.
7. Creutzig U, Ritter J, Budde M, et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer. 1987;60(12):3071-3079.
8. Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J.Clin Oncol. 1985;3(12):1590-1595.
9. Pastore F, Pastore A, Wittmann G, et al. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS.One. 2014;9(4):e95062-
10. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
11. Cuttner J, Conjalka MS, Reilly M, et al. Association of monocytic leukemia in patients with extreme leukocytosis. Am.J.Med. 1980;69(4):555-558.
12. Scott CS, Stark AN, Limbert HJ, et al. Diagnostic and prognostic factors in acute monocytic leukaemia: an analysis of 51 cases. Br.J.Haematol. 1988;69(2):247-252.
13. Kaneko Y, Maseki N, Takasaki N, et al. Clinical and hematologic characteristics in acute leukemia with 11q23 translocations. Blood. 1986;67(2):484-491.
For personal use only.on October 31, 2017. by guest www.bloodjournal.orgFrom
23 Röllig & Ehninger How I treat hyperleukocytosis in AML
14. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380.
15. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
16. Reuss-Borst MA, Klein G, Waller HD, et al. Differential expression of adhesion molecules in acute leukemia. Leukemia. 1995;9(5):869-874.
17. Dixit A, Chatterjee T, Mishra P, et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl.Thromb.Hemost. 2007;13(3):292-298.
18. McKee LC, Jr., Collins RD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimore). 1974;53(6):463-478.
19. Lichtman MA. Rheology of leukocytes, leukocyte suspensions, and blood in leukemia. Possible relationship to clinical manifestations. J.Clin Invest. 1973;52(2):350-358.
20. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk.Lymphoma. 2000;39(1-2):1-18.
21. Lichtman MA, Weed RI. Peripheral cytoplasmic characteristics of leukocytes in monocytic leukemia: relationship to clinical manifestations. Blood. 1972;40(1):52-61.
22. Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood. 1982;60(2):279-283.
23. Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute leukemia. Ther.Apher. 2002;6(1):15-23.
24. Soares FA, Landell GA, Cardoso MC. Pulmonary leukostasis without hyperleukocytosis: a clinicopathologic study of 16 cases. Am.J.Hematol. 1992;40(1):28-32.
25. Cavenagh JD, Gordon-Smith EC, Gibson FM, et al. Acute myeloid leukaemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM-1). Br.J.Haematol. 1993;85(2):285-291.
26. van Buchem MA, Hogendoorn PC, Levelt CN, et al. Development of pulmonary leukostasis in experimental myelocytic leukemia in the Brown-Norway rat. Leukemia. 1992;6(2):142-149.
27. De WM, Renmans W, Jochmans K, et al. Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts. Eur.J.Haematol. 1999;63(3):192-201.
28. Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007;47(10):1843-1850.
For personal use only.on October 31, 2017. by guest www.bloodjournal.orgFrom
24 Röllig & Ehninger How I treat hyperleukocytosis in AML
29. Novotny JR, Muller-Beissenhirtz H, Herget-Rosenthal S, et al. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur.J.Haematol. 2005;74(6):501-510.
30. Stucki A, Rivier AS, Gikic M, et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97(7):2121-2129.
31. Hatfield KJ, Reikvam H, Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr.Med.Chem. 2010;17(36):4448-4461.
32. Hatfield KJ, Bedringsaas SL, Ryningen A, et al. Hypoxia increases HIF-1alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur.Cytokine Netw. 2010;21(3):154-164.
33. Reikvam H, Hatfield KJ, Oyan AM, et al. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur.J.Haematol. 2010;84(3):239-251.
34. Paupert J, Mansat-De M, V, Demur C, et al. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle. 2008;7(8):1047-1053.
35. Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk.Res. 2008;32(8):1221-1227.
36. Piccirillo N, Laurenti L, Chiusolo P, et al. Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis. Am.J.Hematol. 2009;84(6):381-382.
37. Atallah E, Cortes J, O'brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110(10):3547-3551.
38. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90(8):2952-2961.
39. Ganzel C, Becker J, Mintz PD, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26(3):117-122.
40. Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br.J.Haematol. 2009;145(1):24-33.
25 Röllig & Ehninger How I treat hyperleukocytosis in AML
hyperleukocytosis: a systematic review and meta-analysis. Leuk.Res. 2014;38(4):460-468.
43. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J.Clin Oncol. 2008;26(16):2767-2778.
44. Vadhan-Raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann.Oncol. 2012;23(6):1640-1645.
45. Feng X, Dong K, Pham D, et al. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J.Clin Pharm.Ther. 2013;38(4):301-308.
46. Coutsouvelis J, Wiseman M, Hui L, et al. Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br.J.Clin Pharmacol. 2013;75(2):550-553.
47. Darmon M, Guichard I, Vincent F. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. J.Clin Oncol. 2011;29(3):e67-e68.
48. Piro E, Carillio G, Levato L, et al. Reversal of leukostasis-related pulmonary distress syndrome after leukapheresis and low-dose chemotherapy in acute myeloid leukemia. J.Clin Oncol. 2011;29(26):e725-e726.
49. Chang MC, Chen TY, Tang JL, et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am.J.Hematol. 2007;82(11):976-980.
50. Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk.Lymphoma. 2001;42(1-2):67-73.
51. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
52. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-495.
53. Jehn U, Goldel N, Rienmuller R, et al. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia. Med.Oncol Tumor Pharmacother. 1988;5(1):41-47.
54. Andersson BS, Luna MA, Yee C, et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990;65(5):1079-1084.
55. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171-3179.
For personal use only.on October 31, 2017. by guest www.bloodjournal.orgFrom
26 Röllig & Ehninger How I treat hyperleukocytosis in AML
56. Holig K, Moog R. Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia. Transfus.Med.Hemother. 2012;39(4):241-245.
57. Bruserud O, Liseth K, Stamnesfet S, et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus.Med. 2013;23(6):397-406.
58. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin.Thromb.Hemost. 2007;33(4):350-354.
59. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J.Clin Apher. 2010;25(3):83-177.
60. Vahdat L, Maslak P, Miller WH, Jr., et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84(11):3843-3849.
61. Zuckerman T, Ganzel C, Tallman MS, et al. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993-2002.
62. Hunt BJ, Jurd KM. Endothelial cell activation. A central pathophysiological process. BMJ. 1998;316(7141):1328-1329.
63. Mantovani A, Sozzani S, Vecchi A, et al. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb.Haemost. 1997;78(1):406-414.
64. Stefanidakis M, Karjalainen K, Jaalouk DE, et al. Role of leukemia cell invadosome in extramedullary infiltration. Blood. 2009;114(14):3008-3017.
For personal use only.on October 31, 2017. by guest www.bloodjournal.orgFrom
doi:10.1182/blood-2014-10-551507Prepublished online March 16, 2015;
Christoph Röllig and Gerhard Ehninger How I treat hyperleukocytosis in acute myeloid leukemia
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requestsInformation about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprintsInformation about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtmlInformation about subscriptions and ASH membership may be found online at:
digital object identifier (DOIs) and date of initial publication. indexed by PubMed from initial publication. Citations to Advance online articles must include final publication). Advance online articles are citable and establish publication priority; they areappeared in the paper journal (edited, typeset versions may be posted when available prior to Advance online articles have been peer reviewed and accepted for publication but have not yet
Copyright 2011 by The American Society of Hematology; all rights reserved.Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of
For personal use only.on October 31, 2017. by guest www.bloodjournal.orgFrom